One consortium to unite a growing international movement.
The era of genomic sequencing in medicine has arrived.
Scientists have long predicted that newborn sequencing would one day become a routine health check at birth, offering parents early guidance on care that is tailored to their child.
Researchers from around the globe have been independently studying the implementation of newborn sequencing, slowly moving us closer to realizing that goal.
We convened ICoNS to accelerate that process by bringing these world-class experts together to share knowledge, research plans, and results from the original eight studies in newborn sequencing.
This newly founded consortium introduced themselves and their mission to the world at the inaugural International Conference on Newborn Sequencing, held in Boston in 2022.
Since then, we’ve assembled the ICoNS Steering Committee, a governing body of project leaders who founded the consortium, to drive this growing movement steadily toward success.
Now, with all contributing partners under one umbrella, we can concentrate all of the world’s research on newborn genomics into one unified effort to improve public health for all.
The ICoNS Steering Committee
The path forward begins with us.
ICoNS is growing daily, with more and more partners from around the world joining the movement and contributing their research to propel us toward the dream of preventive genomics as routine medicine.
Approaching 30 individual consortium members and the multitude of researchers, healthcare providers, vendors, and laboratories they bring with them, ICoNS is the premier collection of experts in the field.
ICoNS welcomes thought-leaders across all fields that are actively participating in newborn sequencing implementation projects, or are imminently preparing to do so.
The Consortium Members
click to expand
-
Don Bailey, PhD, MeD
EarlyCheck
RTI International
-
Emma Baple, MBBS, MRCPH, PhD
Royal Devon University
NHS Foundation Trust
-
David Bick, MD
Genomics England
-
Amy Brower, PhD
NBSTRN
-
Dr. David Brown
Qatar Precision Medicine Institute
-
Wendy K. Chung, MD, PhD
GUARDIAN Study
Boston Children’s Hospital
-
Lilian Downie MBBS, FRACP, PhD
Victorian Clinical Genetics Services
BabyScreen+
-
Nicolas Encina, MS, MBA
Ariadne Labs
Harvard University
-
Laurence Faivre, MD, PhD
Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs
-
Alessandra Ferlini, MD, PhD
Screen4Care
University of Ferrara
-
Nicolas Garnier, PhD
Pfizer
-
Robert C. Green, MD, MPH
Genomes2People
Brigham and Women’s Hospital
Harvard Medical School
-
Scott Grosse, PhD
CDC, DDNID, NCBDDD, OD
-
Lidewij Henneman, PhD
Amsterdam University Medical Centers
-
Mark David Kilby, DSc, MBBS, MD, FRCPI, FRCOG
Illumina
-
Stephen Kingsmore MD, DSC
BeginNGS, Rady Children's Institute for Genomic Medicine
-
Sebastian Lunke, PhD
BabyScreen+
-
Gert Matthijs, PhD
UZ Leuven
-
Holly Peay, PhD, MS, CGC
EarlyCheck
RTI International
-
Richard Scott, MD, PhD
Genomics England
-
Zornitza Stark, MD
BabyScreen+
-
Kris Van Den Bogaert, MS, PhD
KU Leuven
-
Els Voorhoeve, MS
Centre for Health Protection, National Institute for Public Health and the Environment
-
Melissa Wasserstein, MD
ScreenPlus Chief, Division of Pediatric Genetic Medicine Children's Hospital at Montefiore
-
Bethany Zettler, MS, CGC
BabySeq
Genomes2People
-
Karin Kassahn, PhD
NewbornsInSA
SA Pathology and The University of Adelaide
-
Laurent Servais, MD, PhD
BabyDetect Project
University of Oxford
Hôpital de La Citadelle
-
BOEMER François, PharmD, EuSpLM, PhD
BabyDetect Project
Newborn Screening Centre
Human Genetics
CHU Liege, BELGIUM
-
Jovanka King, PhD FRACP FRCPA BMBS (Hons) BPod
NewbornsInSA
Women’s & Children’s Health Network, SA Pathology & The University of Adelaide
-
Carol W.K. Siu, MBBS, PhD, FRCPA, FRCPath
NewbornsInSA
SA Pathology and The University of Adelaide
-
Petros Tsipouras, MD
FirstSteps
-
Gulcin Gumus, PhD
Research & Policy Senior Manager EURORDIS - Rare Diseases Europe